Centessa Pharmaceuticals (NASDAQ:CNTA) Cut to Hold at Stephens

Stephens lowered shares of Centessa Pharmaceuticals (NASDAQ:CNTA) from a strong-buy rating to a hold rating in a research note released on Tuesday,Zacks.com reports.

Other equities research analysts have also issued reports about the company. Piper Sandler reiterated an “overweight” rating on shares of Centessa Pharmaceuticals in a research report on Friday, January 16th. TD Cowen restated a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. B. Riley Financial raised their price target on Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. Oppenheimer boosted their price objective on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Finally, Wolfe Research lowered shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a report on Tuesday. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $40.00.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ:CNTA opened at $39.69 on Tuesday. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. The company has a 50-day moving average price of $26.93 and a 200-day moving average price of $25.45. The company has a market cap of $5.80 billion, a price-to-earnings ratio of -21.69 and a beta of 1.25. Centessa Pharmaceuticals has a 12 month low of $9.60 and a 12 month high of $40.26.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Monday, April 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.10). As a group, equities analysts anticipate that Centessa Pharmaceuticals will post -1.6 EPS for the current year.

Insider Transactions at Centessa Pharmaceuticals

In related news, insider Iqbal J. Hussain sold 38,951 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total value of $979,617.65. Following the sale, the insider directly owned 57,645 shares of the company’s stock, valued at $1,449,771.75. This represents a 40.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Karen M. Anderson sold 120,029 shares of the stock in a transaction on Friday, March 13th. The stock was sold at an average price of $26.25, for a total value of $3,150,761.25. Following the completion of the transaction, the insider owned 62,085 shares of the company’s stock, valued at approximately $1,629,731.25. This trade represents a 65.91% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 349,073 shares of company stock valued at $9,429,412. Corporate insiders own 7.09% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Millennium Management LLC grew its position in Centessa Pharmaceuticals by 52.9% during the 1st quarter. Millennium Management LLC now owns 609,188 shares of the company’s stock valued at $8,760,000 after purchasing an additional 210,737 shares during the last quarter. Jane Street Group LLC bought a new position in Centessa Pharmaceuticals in the 1st quarter valued at approximately $2,176,000. Geode Capital Management LLC increased its holdings in shares of Centessa Pharmaceuticals by 44.7% in the 2nd quarter. Geode Capital Management LLC now owns 87,435 shares of the company’s stock worth $1,149,000 after purchasing an additional 26,994 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Centessa Pharmaceuticals by 155.4% in the second quarter. JPMorgan Chase & Co. now owns 428,434 shares of the company’s stock worth $5,630,000 after purchasing an additional 260,702 shares during the last quarter. Finally, Legal & General Group Plc lifted its holdings in shares of Centessa Pharmaceuticals by 29.2% during the second quarter. Legal & General Group Plc now owns 98,256 shares of the company’s stock valued at $1,291,000 after purchasing an additional 22,205 shares in the last quarter. 82.01% of the stock is currently owned by institutional investors.

Key Stories Impacting Centessa Pharmaceuticals

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Lilly acquisition reported — Multiple outlets report Eli Lilly will acquire Centessa in a deal worth up to $7.8B; press coverage notes shareholders would receive roughly $38 in cash plus contingent value rights tied to potential upside, which sets a clear takeover premium/floor under the stock. LLY to Buy Centessa — Zacks
• Positive Sentiment: Large call buying — Reports show unusually high volume of call-option purchases, a bullish signal from derivatives traders that may reflect takeover-related arbitrage or speculative upside interest. Investors Purchase Calls — American Banking News
• Neutral Sentiment: Guggenheim reaffirmed “neutral” — Guggenheim left its rating unchanged, signaling no strong analyst upgrade in response to the takeover buzz. Guggenheim Reaffirms — TickerReport
• Neutral Sentiment: Leerink moved to “hold” but raised price target to $40 — A mixed note: downgrading the rating but nudging the target slightly above current market levels, reflecting uncertainty about deal dynamics or timing. Leerink Downgrade / PT — Benzinga
• Negative Sentiment: Multiple analyst downgrades — Several firms (B. Riley, Lifesci Capital, Wolfe Research, Needham, Stephens and others) cut ratings to hold from stronger stances, pressuring sentiment despite the takeover reports. Analyst Downgrades — Zacks Wolfe Research — American Banking News Needham — American Banking News
• Negative Sentiment: Shareholder investigations and class-action alerts — Two law firms announced probes into the proposed sale process and price adequacy, creating legal/transaction risk that can weigh on the stock and complicate closing. Monteverde & Associates — PR Newswire KSF Investigation — BusinessWire
• Negative Sentiment: Earnings miss — Centessa reported Q (EPS -$0.48) that missed consensus (~ -$0.38), an operational disappointment that adds near-term pressure independent of M&A news. Earnings Release — MarketBeat
• Negative Sentiment: Heavy put buying — Separately, unusual volume in put options (10,659 puts, a large jump vs. average) shows some participants betting on downside or using puts for hedging around the deal. (No direct link provided in feed.)

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.